NCT03317015 (NASANIF) is a Phase 3 clinical trial of triamcinolone XRG5029 in Rhinitis Allergic, sponsored by Sanofi.

Who is sponsoring NCT03317015?

NCT03317015 is sponsored by Sanofi.

What drugs are being tested in NCT03317015?

Interventions in NCT03317015: triamcinolone XRG5029, fluticasone.

What condition does NCT03317015 study?

NCT03317015 studies Rhinitis Allergic.

Is NCT03317015 still recruiting?

NCT03317015 is currently completed. Last updated 25 April 2022.

Last reviewed 2022-04-25 · How we verify

NCT03317015: NASANIF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess Efficacy and Safety of Nasacort® Nasal Spray in Comparison With Flixonase® Nasal Spray in Adults Suffering From Perennial Allergic Rhinitis (PAR)

Completed Phase 3 Last updated 25 April 2022

What this trial tests

Phase 3 trial testing triamcinolone XRG5029 in Rhinitis Allergic in 260 participants. Completed in 10 July 2017.

Timeline

30 November 2016

Primary endpoint
10 July 2017

10 July 2017

Quick facts

Lead sponsor	Sanofi
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	260
Start date	30 November 2016
Primary completion	10 July 2017
Estimated completion	10 July 2017

Drugs / interventions tested

triamcinolone XRG5029 — full drug profile →
fluticasone

Conditions studied

Rhinitis Allergic — all drugs for Rhinitis Allergic →

Sponsor

Sanofi — full company profile →

Who can join

Adults 18 to 50, any sex, with Rhinitis Allergic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Primary Objective: * To assess efficacy of Nasacort® (triamcinolone) nasal spray, 55 µg per dose, in comparison with Flixonase® (fluticasone) nasal spray, 50 µg per dose, by reflective total nasal symptom score (rTNSS) (24 h) after 28 days of treatment compared with baseline (0 day of treatment) in adult patients suffering from PAR (perennial allergic rhinitis). Secondary Objectives: * To evaluate safety of Nasacort® (triamcinolone) nasal spray, in comparison with Flixonase® (fluticasone) administered for 28 days by assessment of adverse events reports. * To evaluate patient and physician satisfaction after 28 days of treatment by 5-point scale. * To estimate improvement of quality of life during the study by mini Rhinoconjunctivitis Quality of Life Questionnaire (miniRQLQ).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Triamcinolone Acetonide versus Fluticasone Propionate in the Treatment of Perennial Allergic Rhinitis: A Randomized, Parallel-Group Trial.
Karaulov AV, Vylegzhanina T, Ovchinnikov A, Chernikova M, et al · · 2019 · cited 8× · PMID 30879006 · DOI 10.1159/000497160
Triamcinolone Acetonide in the Treatment of Perennial Allergic Rhinitis: A post hoc Analysis of Quality of Life during a Phase III Study.
Karaulov AV, Nenasheva N, Smolkin Y, Maslakov A, et al · · 2022 · cited 3× · PMID 34515149 · DOI 10.1159/000518753
Triamcinolone Acetonide in the Treatment of Perennial Allergic Rhinitis: A post hoc Efficacy Analysis of a Phase III Study Performed in Russia.
Karaulov AV, Ilina NI, Shartanova N, Maslakov A, et al · · 2022 · cited 2× · PMID 34535609 · DOI 10.1159/000518754

Verify or expand the search:

Other recruiting trials for Rhinitis Allergic

Currently open trials in the same condition.

NCT06890572 — Validation of the Efficacy of Air Purifiers in Indoor Environment and Allergic Symptoms in Allergic Rhinitis Patients · NA · recruiting

Other Sanofi trials

Trials by the same sponsor.

NCT07282795 — Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe · not yet recruiting
NCT06694025 — Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe. · not yet recruiting
NCT07222189 — A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Dise · Phase 2 · not yet recruiting
NCT07484230 — A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Partic · Phase 3 · not yet recruiting
NCT07547436 — A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age Wi · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03317015 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sanofi
Last refreshed: 25 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03317015.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing